Gene Therapy Tested in Blood Cancers That Return or Do Not Respond
Tests VNX-101 gene therapy in people with relapsed or refractory CD19-positive blood cancers.
Key facts
- Who runs it
- Vironexis Biotherapeutics Inc.
- Where
- Chapel Hill, Columbus, Denver, Duarte, Houston, Jacksonville, Los Angeles, Nashville, Portland, Rochester, and Valhalla, United StatesSee the 11 sites
- Trial code
- Registry title
- Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 32 people, planned
- Started
- 30 May 2025
- Expected to end
- Sept 2031
- Type of study
- Interventional
- Treatments tested
- Dose Level 1, VNX-101
- Dose Level 2, VNX-101
- Dose Level 3, VNX-101
- Dose Level 4, VNX-101
- Record updated
- 26 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with leukemia or lymphoma that has come back or has not responded to treatment, and whose cancer cells carry the CD19 marker.
- Age
- Part 1: 18-90 years. Part 2: 13-90 years.
- Sex
- All sexes can join.
- Disease stage
- Relapsed or refractory CD19-positive leukemia or lymphoma, as defined in the protocol.
- Earlier treatment
- Chemotherapy must not have been given within the protocol-specified time before joining.
- Biomarker or test result
- CD19-positive expression is required. A specific AAV capsid total antibody result is also required, per the protocol.
Main reasons for not taking part
- Liver damage (AST or ALT above 2x the upper limit of normal)
- History of thrombotic microangiopathy or cardiomyopathy, or signs of sensory neuropathy
- Pregnant or nursing women
- Acute graft versus host disease grade 2-4, or chronic graft versus host disease of any grade
- History of allergy or toxicity related to corticosteroids
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age: Part 1: 18-90 years of age, Part 2: 13-90 years of age
- Relapsed or refractory CD-19 positive leukemia or lymphoma as defined in the protocol
- CD19-positive expression
- AAV specified capsid total antibody per protocol requirement
- Protocol-specified ranges for renal, liver, cardiac and pulmonary function
- Protocol-specified ranges for hematology parameters
Who cannot take part
- Chemotherapy given within the protocol-specified discontinuation timelines; Other Inclusion/Exclusion criteria to be applied per protocol
- History of thrombotic microangiopathy or cardiomyopathy, or evidence of sensory neuropathy
- Acute Graft versus Host Disease (GvHD): Grade 2-4 or chronic GvHD of any grade
- History of hypersensitivity to corticosteroids or history of corticosteroid-related toxicity
- Hepatoxicity (AST or ALT > 2x upper limit of normal)
- Pregnant or nursing (lactating) women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 13 and 90 years old?
Where in United States
- University of North Carolina at Chapel Hill/ University of North Carolina Medical CenterChapel Hill, United StatesContact: Lacey Williams, MDTaking people
- The Ohio State University -Wexner Medical CenterColumbus, United StatesContact: Gregory Behbehani, MD, PhDTaking people
- Colorado Blood Cancer InstituteDenver, United StatesContact: Allen RehaTaking people
- City of HopeDuarte, United StatesContact: Anthony Stein, MDTaking people
- University of Texas - MD Anderson Cancer CenterHouston, United StatesContact: Nicholas J Short, MDTaking people
- Mayo Clinic, Clinical Trials Referral OfficeJacksonville, United StatesContact: Allen RehaTaking people
- Valkyrie Clinical TrialsLos Angeles, United StatesContact: Myo ZawTaking people
- TriStar BMTNashville, United StatesContact: Stephen Strickland, MDTaking people
- Oregon Health Science UniversityPortland, United StatesContact: Knight Cancer Institute Clinical TrialsTaking people
- Mayo Clinic, Clinical Trials Referral OfficeRochester, United StatesContact: Allen RehaTaking people
- New York Medical CollegeValhalla, United StatesContact: Mitchell Cairo, MDTaking people
About the trial
What the trial wants to find out
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
The group in the trial
- Group 1/Group 2/Group 3/Group 4Treatment being tested
Treatment: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, and Dose Level 4, VNX-101
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Plain-language title
- Gene Therapy Tested in Blood Cancers That Return or Do Not RespondGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06533579, who can take part
- Record updated
- 26 October 2026